- Print Magazine
- Digital Magazine
- Newsletter
Latest News (Endcap)
A growing body of evidence links Americans taking GLP-1 prescription drugs for type 2 diabetes and chronic weight management to a decline in grocery basket size. This is a worrying sign for food retailers, as sales of GLP-1 medications are forecast to increase steadily for years to come. But there is an upside for grocers and brands agile enough to adapt their assortments to meet the needs of consumers who feel better physically and emotionally as the weight comes off.
GLP-1 (glucagon-like peptide-1) drugs were initially approved by the Food & Drug Administration (FDA) in 2005 as a treatment for type 2 diabetes. However, reports that GLP-1 meds resulted in weight loss led to medical trials, which prompted the FDA to approve Zaxenda for chronic weight management in 2014. Wegovy followed in 2021. Last month, the FDA also approved Wegovy “to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease” who are either obese or overweight.
Research by Chicago-based Numerator published in November found that 47% of GLP-1 users take the meds for weight loss and another 14% for diabetes and weight loss. The average patient wants to drop 15 or more pounds. Numerator found that, during the first nine months of 2023, GLP-1 patients pursuing weight loss purchased 8.6% fewer units and cut spending on food 3.0% compared to non-users at -6.5% and -0.5%. GLP-1 users who over-index against non-users include Gen X, 43%; suburban, 39%; high-income, 35%; and Black or Hispanic, 31%.
“We definitely do see a slight change compared to the total population, we do see a slight pullback in overall basket,” John Furner, president and CEO of Bentonville, Ark.-based Walmart U.S., told Bloomberg last year. “Just less units, slightly less calories.”
Gary Stibel, founder and CEO of The New England Consulting Group, Westport, Conn., says that the growth of GLP-1 drugs will jump as more products come to market and are approved to treat different conditions.
“The newer drugs are so damned effective. They work so well that the likelihood that we will have 10%, 15%, or 20% of the adult population of the U.S. on these drugs is very high,” says Stibel. And that will likely have a profound effect on food sales.
“People who are on GLP-1s tend to change their behavior,” he explains. “It’s not just that they eat less; they eat differently. They start thinking differently about their own health, their own appearance, and what the food they put in their bodies does. They are eating less frozen pizza, less frozen entrees, and less ice cream. That’s a fact.” However, there are also opportunities for growth, according to Stibel, who says consumer education will drive sales of better-for-you foods like frozen vegetables.
‘People who are on GLP-1s tend to change their behavior. It’s not just that they eat less; they eat differently.’
“Most of the vegetables consumers are eating are fresh because they don’t know that frozen vegetables have more nutrients.” Plus, “Frozen vegetables are more convenient. They don’t go bad. You don’t throw them out.”
Tom McGough, evp and co-COO for Chicago-based Conagra Brands, told attendees at the Consumer Analyst Group of New York Conference in Boca Raton, Fla., in February that his company sees opportunities within its frozen foods portfolio.
“Frozen meals are portion-controlled,” McGough said. “They provide vegetable nutrition and they’re high in protein.”
Stibel says that frozen and refrigerated store brand manufacturers have so far “totally missed the mark” when it comes to developing items for GLP-1 users.
“Retailers need to be much more aggressive with their private label suppliers because change benefits private label early movers,” he says. “The challenge for retailers is not just around the product. It’s how they can help educate consumers. Dietitians can play a huge role here.”